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1 Executive summary 
This report presents the findings of a systematic review commissioned by the NICE Centre for Public 
Health to support the development of updated guidance on tuberculosis. The review question is: 
 What strategies and interventions are effective and cost effective in increasing the uptake of 
BCG vaccination among people at increased risk of developing active or latent TB? 
We searched a range of database sources, including both health and non-health databases, from 
1993 to 2013. We included any outcome evaluation study which measured BCG uptake as an 
outcome and was conducted in a high-income (OECD) country. Quality assessment and data 
extraction were carried out using standardised forms from the NICE methods manual. Data were 
synthesized narratively. 
Eight studies were included in the review. One study was graded as high quality (++), and the other 
seven as low quality (–). Six studies were conducted in the UK, one in Sweden and one in Turkey. The 
findings of the studies are summarised in the evidence statements below. 
Evidence statement 1: Staff training 
There is evidence from six studies (four UK and two from other countries) that interventions 
involving staff training may increase the uptake of BCG vaccination. One RCT (Griffiths et al., 2007 
(++)) shows significantly higher uptake in the intervention group, with an odds ratio of 9.52 (95% CI 
4.0–22.7). Five BA studies showed some increase in uptake (Athavale et al., 2006 (–); Gill and Scott, 
1998 (–); Romanus, 2005 (–); Tseng et al., 1997 (–); Uskun et al., 2008 (–)), although in only two 
cases was statistical significance measured, and in neither of these did the increase reach 
significance (Tseng et al., 1997 (–); Uskun et al., 2008 (–)). The RCT involved training clinical staff to 
identify people eligible for BCG vaccination, computer-based reminders to staff, and financial 
incentives to primary care practices for carrying out TB screening. The BA studies generally focused 
mainly on staff training and did not use incentives. 
Applicability 
Most evidence is applicable to BCG vaccination in the UK. Four studies in this category (Athavale et 
al., 2006 (–); Gill and Scott, 1998 (–); Griffiths et al., 2007 (++); Tseng et al., 1997 (–)) were carried 
out in the UK, and one (Romanus, 2005 (–)) in Sweden, which has broadly similar patterns of TB 
infection and BCG policy to the UK. One study (Uskun et al., 2008 (–)) was carried out in Turkey, 
which has a policy of universal neonatal BCG vaccination, and may be less applicable. 
 
Evidence statement 2: Reminders to clinical staff 
One BA study (Chappel and Fernandes, 1996 (–)) appears to show that computerised reminders to 
hospital staff can increase the uptake of BCG vaccination. However, the data are difficult to interpret 
as the criteria for eligibility for BCG were defined differently at pre- and post-test. 
Applicability 
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This evidence is directly applicable to BCG vaccination in the UK as the study was conducted in the 
UK. 
 
Evidence statement 3: Contact tracing interventions 
There is inconclusive evidence from one BA study (Ansari et al., 1998 (–)) as to whether revised 
contact tracing protocols can increase the uptake of BCG vaccination. 
Applicability 
This evidence is directly applicable to BCG vaccination in the UK as the study was conducted in the 
UK.




Current UK guidance on vaccination for tuberculosis (TB)1 recommends that Bacillus Calmette-
Guérin (BCG) vaccine should be offered to the following groups: 
 infants living in high-prevalence areas of the UK (annual incidence  ≥40/100,000); 
 infants  and children up to 16 years with a parent or grandparent born in a high-
prevalence country; 
 children up to 16 years who are contacts of cases of respiratory TB; 
 children up to 16 years who were born in or have lived for at least three months in a 
high-prevalence country; 
 healthcare workers and laboratory staff who will have contact with patients or clinical 
materials; 
 veterinary and staff such as abattoir workers who handle animal species known to be 
susceptible to TB, e.g. simians; 
 staff of prisons, care homes for the elderly, hostels for homeless people and facilities 
accommodating refugees and asylum seekers. 
This policy has been in place since 2005. Prior to that date, there was a universal programme of BCG 
vaccination for adolescents, in addition to selective vaccination for neonates and contacts of TB 
cases along similar lines to the post-2005 policy.   
A range of strategies may be employed to increase the uptake of BCG vaccination among relevant 
groups. The aim of this review is to synthesize evidence from outcome evaluation studies about the 
effectiveness of interventions to increase BCG uptake. This review is supplemented by the review of 
reviews produced for the same phase of this project, which synthesizes review-level evidence on 
interventions to increase the uptake of vaccination in general. 
3 Methods 
This review was conducted according to the methods guidance set out in the current (third) edition 
of Methods for the development of NICE public health guidance. 
3.1 Review question 
The review question is: 
 What strategies and interventions are effective and cost effective in increasing the uptake of 
BCG vaccination among people at increased risk of developing active or latent TB? 
3.2 Searching 
3.2.1 Database searches 
                                                          
1
 Salisbury D, Ramsay M, Noakes K, eds. (2006). Immunisation against infectious disease: The green book 
(London: TSO/DH), pp. 397-8. Cf. also the previous NICE Clinical Guideline on TB (CG117).  
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A comprehensive search strategy was developed in consultation with the CPH team and the 
Guideline Development Group. The following database sources were searched in July 2013. The 
searches were limited from 1993 to the most recent records (with the exception of SCI, SSCI and 
Conference Proceedings Citation Index, which were run from 2011-current to access recent grey 
literature and conference proceedings).  
 ASSIA 
 British Education Index 
 British Nursing Index 
 CINAHL 
 Cochrane Library 









 Science Citation Abstracts 
 Social Policy and Practice 
 Sociological Abstracts 
The search strategy took the following form: 
(TB) AND (BCG) AND (terms for uptake OR terms for specific intervention types, personnel or 
settings OR terms for effectiveness study methods) 
A filter was used to exclude studies on animals. No language restriction was placed on the searches 
(although in subsequent screening, non-English-language references were excluded). The full 
database search records can be found in Appendix 1. 
3.2.2 Other searches 
We searched the following websites for unpublished data: 
 NICE via www.nice.org.uk 
 Public Health Observatory via www.apho.org.uk 
 Public Health England via www.gov.uk/government/organisations/public-health-england 
We searched Google using a simplified version of the search string used for the database searches 
and scanned the first 100 results. We searched PubMed using a time-limited search to identify any 
new items. We chased citations from all items included on full text, and conducted forward citation 
chasing on Web of Science. We also searched the British Library’s Ethos database 
(http://ethos.bl.uk/) using a simplified search string to identify unpublished theses.  




EPPI-Reviewer 4 software was used to manage data. The following inclusion criteria were applied: 
1) Is the study an outcome evaluation of an intervention? (To be included here a study had to: (a) 
involve some intervention (of any kind, e.g. including practice changes, strategies, protocols etc.);  
and (b) report at least some pre- and post-test outcome data (or use random assignment to 
intervention and comparison groups), i.e. trials, one-group before-after studies, and retrospective or 
observational studies which reported clear pre and post data were included.) 
2) Does the study measure uptake of BCG vaccination as an outcome? 
3) Was the study conducted in a high-income country (current OECD member)? 2 
4) Is the study report in English? 
5) Was the study report published in 1993 or later? 
An initial random sample of 10% of titles and abstracts was screened by two reviewers 
independently, with differences resolved by discussion. Agreement at this stage was 99.2%, with 
kappa = 0.85. On the basis of this agreement, subsequent titles and abstracts were screened by one 
reviewer alone. The full text of all references which met criteria, or where it was unclear if they met 
the criteria, was retrieved and re-screened to the same criteria by two reviewers independently, 
with differences resolved by discussion.  
3.4 Quality assessment, data extraction and synthesis 
Review quality was assessed, and data extracted, using the tools in the methods manual (NICE, 
2012). Quality assessment and data extraction were conducted by one reviewer and checked in 
detail by a second reviewer. Data were synthesized narratively. 
4 Results 
4.1 Flow of literature through the review 






                                                          
2
 These are: Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mexico, Netherlands, New 
Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, USA 







Figure 1. Flow of literature through the review 
 
4.2 Results of quality assessment 
The QA tool (NICE, 2012) rates each study on a number of domains and gives an overall rating (high, 
medium or low) to each study on internal and external validity. With one exception, all studies 
received a low internal validity rating, largely due to poor reporting of methods, and the use of non-
comparative designs. Five studies received medium external validity ratings (although this was 
interpreted liberally, to include any study providing more than minimal information about its context 
or population), two low and one high. Table 1 provides a summary of the QA results.
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Population Method of allocation to intervention/comparison Outcomes Analysis Summary 
 1.1 1.2 1.3 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 
2.1
0 
3.1 3.2 3.3 3.4 3.5 3.6 4.1 4.2 4.3 4.4 4.5 4.6 5.1 5.2 
Ansari 1998 BA + + – NA + NA NA – NA NA NA ++ + + + + + NA + NA NA NR – – NA – + 
Athavale 2006 BA + + – NA + NA NA – NA NA NA ++ ++ + + + ++ NA ++ NA NA NR NR – NA – + 
Chappel 1996 BA – + – NA + NA NA – NA NA NA ++ + – + + ++ NA ++ NA NA NR – + NA – – 
Gill 1998 BA + + + NA + NA NA – NA NA NA ++ + – + + ++ NA ++ NA NA NR NR – NA – + 
Griffiths 2007 RCT + + + ++ ++ ++ + + NR ++ ++ ++ ++ + + ++ ++ + + ++ ++ ++ ++ ++ ++ ++ ++ 
Romanus 2006 BA + + ++ NA – NA NA – NA NA NA + + + + + ++ NA ++ NA NA NR NR – NR – + 
Tseng 1997 BA + ++ – NA – NA NA – NA NA NA ++ ++ + + + ++ NA + NA NA NR + + + – – 
Uskun 2008 BA + – – NA + NA NA ++ NA NA NA – + + + ++ ++ NA + NA NA NR + – + – + 
 
Key to questions: 
1.1 Is the source population or source area well described? 
1.2 Is the eligible population or area representative of the source population or area? 
1.3 Do the selected participants or areas represent the eligible population or area? 
2.1 Allocation to intervention (or comparison). How was selection bias minimised? 
2.2 Were interventions (and comparisons) well described and appropriate?  
2.3 Was the allocation concealed?  
2.4 Were participants and/or investigators blind to exposure and comparison?  
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2.5 Was the exposure to the intervention and comparison adequate?  
2.6 Was contamination acceptably low?  
2.7 Were other interventions similar in both groups?  
2.8 Were all participants accounted for at study conclusion? 
2.9 Did the setting reflect usual UK practice?  
2.10 Did the intervention or control comparison reflect usual UK practice?  
3.1 Were outcome measures reliable?  
3.2 Were all outcome measurements complete?  
3.3 Were all important outcomes assessed?  
3.4 Were outcomes relevant?  
3.5 Were there similar follow-up times in exposure and comparison groups?  
3.6 Was follow-up time meaningful?  
4.1 Were exposure and comparison groups similar at baseline? If not, were these adjusted?  
4.2 Was Intention to Treat (ITT) analysis conducted?  
4.3 Was the study sufficiently powered to detect an intervention effect (if one exists)?  
4.4 Were the estimates of effect size given or calculable?  
4.5 Were the analytical methods appropriate?  
4.6 Was the precision of intervention effects given or calculable? Were they meaningful?  
5.1 Are the study results internally valid? (i.e. unbiased)  
5.2 Are the study results generalisable to the source population? (i.e. externally valid) 
 
Key to sections 1-4: 
++ The study has been designed/conducted in such a way as to minimise the risk of bias 
+ Either the answer to the checklist question is not clear from the way the study is reported, or the study may not have addressed all potential sources of 
bias  
- Significant sources of bias may persist 
NR The study fails to report this particular question  
NA Not applicable given the study design 
 
Key to section 5: 
++ All or most of the checklist criteria have been fulfilled; where they have not been, the conclusions are very unlikely to alter 
+ Some of the checklist criteria have been fulfilled, where they have not, or not adequately described, the conclusions are unlikely to alter 
- Few or no checklist criteria have been fulfilled and the conclusions are likely to alter 
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4.3 Characteristics of the included studies 
Full details of the included studies are given in the evidence tables in Appendix 2. Table 2 shows in 
which country the studies were conducted, and gives a brief summary of the interventions, 
populations and settings investigated in the studies.  










BA UK TB clinic Contacts of 
cases 
Revised protocol for 
TB contact screening: 
contacts discharged 
or referred to chest 






BA UK Maternity 
ward 
Neonates Staff training to offer 
BCG vaccination to 
neonates at risk of 
TB; reminders to 
mothers; promotion 









BA UK Maternity 
ward   
Neonates Computer reminders 
to obstetric staff, 










Neonates Training for health 
visitors and midwives 
to offer BCG 
vaccination; at-risk 
mothers identified at 
antenatal visits, 
given information 
about BCG and asked 





medical officers to 
health visitors / 
– 











Staff training (based 
on social influence 
theory) – educational 
visits to practices by 
research GP and 
nurse to promote TB 













BA Sweden Child 
health 
centres 
Neonates Information to 
nurses about change 
from universal to 
selective vaccination 
and definitions for 









Neonates Health visitors 
trained to identify 
and refer at-risk 
children; leaflets 
about BCG for 





BA Turkey Primary 
care 









sessions lasted 3 




4.4 Study findings 
NICE: Improving uptake of BCG for TB: Final report  
 
14 
As can be seen from the summaries above, only one study (Griffiths et al., 2007 (++)) used any kind 
of comparative design; this study was a high-quality study which used a prospective, cluster 
randomised controlled trial design. The other seven studies, which have been described as ‘before-
after’ studies in the tables, generally used retrospective methods to analyse impacts of changes in 
policy at the level of particular practices (many also had very substantial limitations in design and 
reporting).  
Most studies (Athavale et al., 2006 (–); Gill and Scott, 1998 (–); Griffiths et al., 2007 (++); Romanus, 
2005 (–); Tseng et al., 1997 (–); Uskun et al., 2008 (–)) concerned interventions with a substantial 
component of staff training. These have been counted as ‘staff training interventions’ below 
(although several interventions also contain other components). The intervention in one study 
(Chappel and Fernandes, 1996 (–)) has been categorised as ‘reminders’, and the final one (Ansari et 
al., 1998 (–)) as ‘screening policy change’.  
4.4.1 Staff training interventions 
Comparative study 
Griffiths et al. (2007 (++)) is considered first in this section, as it was the only comparative study; 
non-comparative studies are considered further below. Griffiths et al. (2007 (++)) evaluated an 
intervention in primary care in Hackney, London, an ethnically mixed and socio-economically 
deprived area. The study design used was a cluster-randomised controlled trial, with randomisation 
at the level of GP practices. A total of 50 practices were included at baseline, with outcomes 
measured on all new patients registering with those practices over a two-year period (a total sample 
of N=93,970), although data on the BCG uptake outcome were available only for 43 practices. The 
included population was ethnically mixed (approx. 43% white, 23% black, 10% Asian), and included a 
substantial number of new immigrants (approx. 260 per practice registered over the 2 year study 
period). However, outcome measures were not disaggregated by group. 
The main goal of the intervention was to promote screening for TB, rather than BCG uptake alone. A 
specialist nurse and researcher GP carried out educational visits to intervention practices to promote 
TB screening and raise awareness of guidelines, and made a follow-up phone call after the visit (on-
going telephone support was also available). This component of the intervention was based on the 
social influence theory of behaviour change. Reminders were also incorporated into intervention 
practices’ computer systems. Practices were also provided with equipment for TB testing and 
financial incentives for carrying out tests (£7 each). 
The relevant outcome for this review was BCG coverage in people aged 5 years or older (although it 
is not entirely clear whether this refers to total coverage in the population or new vaccinations 
carried out; it would appear the latter). Over the period of the study, BCG coverage was 2.68% in 
patients of intervention practices (N of practices = 22), and 0.38% in patients of control practices 
(N=21), giving an odds ratio of 9.52 (95% CI 4.0–22.7).  
This was a methodologically robust study, with appropriate checks in place to reduce bias. It found 
that a staff training intervention had the effect of increasing BCG uptake rates in an ethnically mixed 
population. However, the study has some limitations for the purposes of this review. The 
intervention did not mainly focus on increasing BCG uptake, and detailed data for this outcome were 
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not provided in the report. In addition, the intervention had a number of components, including 
practice-level incentives as well as training and support, and it is unclear which components may 
have made the greatest contribution to the success of the intervention.  
Non-comparative studies 
The findings from the observational studies are considerably less reliable from a methodological 
perspective, since they do not include control groups, and hence any change in outcome cannot be 
securely attributed to the intervention. This type of study may, however, provide some useful 
indicative evidence of the possible effects of interventions in real-life settings, withstanding some of 
the limitations of these studies as described below.  
Athavale et al. (2009 (–)) evaluated an intervention in a maternity hospital in Glasgow serving a 
deprived population with a substantial proportion of immigrants (full demographic detail was not 
reported). The study used a retrospective before-after design. The intervention involved training 
staff to identify neonates at risk of TB, and recommending BCG to eligible mothers as part of the 
routine pre-discharge examination; a specialist vaccination clinic was also set up in the hospital 
outpatient area. Baseline measures in this study found a low uptake of BCG (N=5 over 1 year, 
percentage not reported). After the intervention, 606 infants were identified as eligible for BCG, of 
whom 557 were vaccinated in the specialist clinic and a further nine in the community (93%). 
Statistical significance was not reported. 
Gill and Scott (1998 (–)) evaluated an intervention at antenatal clinics and a maternity ward in a 
Bolton, an area where approximately 8% of the population is from ethnic minority groups, most 
from the Indian subcontinent. Approximately 20% of infants born each year are considered eligible 
for BCG vaccination. The study used a retrospective before-after design. The intervention comprised 
of moving the responsibility for BCG vaccination from community health officers to midwives and 
health visitors. Specifically, midwives identified women whose infant would be indicated for BCG 
vaccination at her first visit to the antenatal clinic. At following visits the women were given 
additional information about the vaccination (details not reported) and asked to give consent for the 
infant to be vaccinated on the maternity ward following birth. To support these changes, midwives 
and health visitors attended training sessions focussed on tuberculosis, administration of BCG, 
anaphylaxis, and paediatric resuscitation. All those who completed the course received a certificate 
of attendance and a copy of the BCG vaccination policy.  
The primary outcome of interest was the number of children for whom BCG was indicated who had 
received it within the first three months of life. The outcomes show a large increase in the number 
of eligible infants receiving BCG: 1993 (pre) 6%; 1994 (post) 88%; 1995 (post) 90%; 1996 (post) 89%. 
However, statistical significance is not reported. Again, it is unclear how the denominator of the 
fraction (i.e. the number of eligible infants) was calculated, and whether it was consistent between 
pre and post measures.  
Romanus (2009 (–)) describes the impact of the selective vaccination programme in Sweden, where 
approximately 12% of the population is foreign-born, using a retrospective before-after design. The 
study is mainly concerned with epidemiological monitoring data, but does include limited 
information about a policy change regarding BCG vaccination. BCG vaccination policy changed from 
universal to selective (mainly targeting children of foreign-born parents) in 1975, leading to a drop in 
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coverage from “at least 95%” to “below 2%” (full outcome data are not reported). A programme was 
then implemented in which nurses at child health centres were given information about the reasons 
for the change to selective vaccination, and in particular, about the case definition for risk groups to 
be vaccinated (no further details of the intervention are reported). This led to an increase in 
coverage, with coverage reaching 15% total among cohorts born from 1998 to 2002 (estimated at 
88% among eligible groups). Statistical significance was not reported.   
Tseng et al. (1997 (–)) evaluated the implementation of a new BCG policy in South London 
(Lewisham, Southwark and Lambeth), an ethnically diverse area where TB notification is highest in 
people of black African and Indian subcontinent ethnicity. The study used a retrospective before-
after design. The nature and timing of the intervention in this study are not clearly reported, but it 
appeared to include the following components: a consultant in communicable disease control met 
with clinical directorates of acute hospitals to encourage them to ensure BCG was available for at-
risk neonates; health visitors received training in order to identify and refer eligible infants to BCG 
vaccination clinics; and leaflets about BCG were distributed to parents and healthcare professionals.  
The primary outcomes of interest were the number of BCG vaccinations given and the proportion of 
eligible infants given BCG. Prior to the intervention 11% of eligible infants received BCG (36 of 342), 
and 15% following the intervention (30 of 210). The authors report that this change was not 
statistically significant.  
Uskun et al. (1996 (–)) evaluated an intervention designed to increase knowledge of primary 
healthcare workers and vaccination coverage Isparta, Turkey, where BCG vaccination is 
recommended universally as part of the standard vaccination schedule. The intervention focused on 
training healthcare providers. Three-day workshops for primary healthcare providers, which 
included both lectures and activities, were implemented. The content included vaccines, national 
vaccination schedule, cold-chain management, planning and regulation of immunization, tracking 
the trends and increase in vaccination coverage, and immunization recording. Attendance and 
participation in the workshops was mandatory.  
In the pre-test period, BCG coverage was 25.4% (1,287 of 5,057), and at post-test 25.8% (1,294 of 
5,020). The study authors report that this increase was statistically significant (at p<0.001), but no 
details of the analysis are given, and recalculation of the reported data would suggest that it is not 
significant at p<0.05, so there appears to be some error in the reported analysis. The results of this 
study may not be applicable to the UK context as BCG vaccination is recommended for all infants in 
Turkey, rather than being targeted as in the UK. 
Evidence statement 1: Staff training 
There is evidence from six studies (four UK and two from other countries) that interventions 
involving staff training may increase the uptake of BCG vaccination. One RCT (Griffiths et al., 2007 
(++)) shows significantly higher uptake in the intervention group, with an odds ratio of 9.52 (95% CI 
4.0–22.7). Five BA studies showed some increase in uptake (Athavale et al., 2006 (–); Gill and Scott, 
1998 (–); Romanus, 2005 (–); Tseng et al., 1997 (–); Uskun et al., 2008 (–)), although in only two 
cases was statistical significance measured, and in neither of these did the increase reach 
significance (Tseng et al., 1997 (–); Uskun et al., 2008 (–)). The RCT involved training clinical staff to 
identify people eligible for BCG vaccination, computer-based reminders to staff, and financial 
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incentives to primary care practices for carrying out TB screening. The BA studies generally focused 
mainly on staff training and did not use incentives. 
Applicability 
Most evidence is applicable to BCG vaccination in the UK. Four studies in this category (Athavale et 
al., 2006 (–); Gill and Scott, 1998 (–); Griffiths et al., 2007 (++); Tseng et al., 1997 (–)) were carried 
out in the UK, and one (Romanus, 2005 (–)) in Sweden, which has broadly similar patterns of TB 
infection and BCG policy to the UK. One study (Uskun et al., 2008 (–)) was carried out in Turkey, 
which has a policy of universal neonatal BCG vaccination, and may be less applicable. 
4.4.2 Reminders to clinical staff 
Chappel and Fernandes (1996 (–)) evaluated an intervention in the obstetric unit of a district hospital 
in Milton Keynes. The study used a retrospective before-after design. The intervention involved the 
installation of a computer which provided automated reminders to staff to offer BCG to eligible 
infants. The outcomes were the number of vaccinations conducted, and the proportion of eligible 
infants vaccinated. However, the latter outcome are difficult to interpret as the number of eligible 
infants was estimated differently at pre-test and at post-test, with the pre-test number extrapolated 
from Census data, and the post-test number derived from the data recorded on the computer. The 
outcomes, presented in Table 3, show a significant increase in the number of BCG vaccinations 
given, and, with the caveat above, appear to show an increase in the proportion of the eligible 
population vaccinated.  
Table 3. Outcome data from Chappel and Fernandes (1996 (–))  









95% CI (%) 
1988 42 176 23.9 17.7-30.3 
1989 31 169 18.3 12.5-24.2 
1990 33 171 19.3 13.4-25.2 
1991 – new system 
introduced 
140 NR NR NR 
1992 234 445 52.6 47.9-57.2 
1993 354 457 77.5 73.6-81.3 
 
Evidence statement 2: Reminders to clinical staff 
One BA study (Chappel and Fernandes, 1996 (–)) appears to show that computerised reminders to 
hospital staff can increase the uptake of BCG vaccination. However, the data are difficult to interpret 
as the criteria for eligibility for BCG were defined differently at pre- and post-test. 
Applicability 
This evidence is directly applicable to BCG vaccination in the UK as the study was conducted in the 
UK. 
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4.4.3 Contact tracing interventions 
Ansari et al. (1998 (–)) focused on a revised protocol for TB contact tracing, implemented in a 
specialist clinic in South Glamorgan, Wales (an area of mostly white ethnicity and low TB 
prevalence). The study design used was a retrospective before-after design. Unfortunately the 
previous protocol is not described in this study, so the intervention cannot be readily characterised, 
although the new protocol is described as ‘simplified’. 
The main outcome used in this study was number of BCG vaccinations carried out; the authors also 
report when BCG was given ‘inappropriately’ and when it was omitted ‘inappropriately’ (i.e., 
respectively, given when it should not have been, and not given when it should have been), although 
it is unclear what eligibility criteria were used. The study findings are presented in Table 4. Statistical 
significance was not reported, so the effectiveness of the intervention cannot readily be evaluated, 
although there appears to have been some decline in the number of patients for whom BCG was 
inappropriately omitted. 
Table 4. Outcome data from Ansari et al. (1998 (–))   
 Pre Post 
BCG given 119 (20%) 161 (22.8%) 
    BCG given appropriately 119 (100%) 153 (95%) 
    BCG given inappropriately 0 (0%) 8 (5%) 
BCG inappropriately omitted 38 (6.4%) 2 (0.3%) 
 
Evidence statement 3: Contact tracing interventions 
There is inconclusive evidence from one BA study (Ansari et al., 1998 (–)) as to whether revised 
contact tracing protocols can increase the uptake of BCG vaccination. 
Applicability 




5.1 Overview of findings 
One reasonably robust cluster-RCT finds that an intervention in primary care including training of 
staff, financial incentives to practices, and computer reminders can increase the number of BCG 
vaccinations carried out in a deprived and ethnically diverse area (Griffiths et al., 2007 (++)). Two BA 
studies find that staff training in conjunction with a special vaccination clinic (Athavale et al., 2006 (–
)) or staff training in conjunction with a policy change making midwives and health visitors primarily 
responsible for vaccination (Gill and Scott, 1998 (–)), may be effective in increasing BCG uptake. 
However, two further BA studies (Tseng et al., 1997 (–); Uskun et al., 2008 (–)) suggest that 
education of staff alone may be ineffective in increasing BCG uptake. 
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One study (Chappel and Fernandes, 1996 (–)) suggests that computerised reminders may be 
effective in increasing BCG uptake. There is no usable evidence on any other intervention types. No 
studies of cost-effectiveness of any intervention were located. 
The findings thus tentatively suggest that interventions involving the provision of information to 
clinical staff are likely to be effective if they are carried out in conjunction with other components, 
such as changes to clinical policy, automated reminders, financial incentives or on-going support for 
healthcare providers. This is broadly in line with the findings of the review of reviews carried out in 
parallel to this review. However, the evidence is insufficient to give a detailed understanding of how 
different intervention components may interact. 
5.2 Strengths and weaknesses of the review 
This systematic review was carried out in accordance with NICE Centre for Public Health methods 
guidance and incorporated a range of strategies to reduce bias. We carried out comprehensive, 
systematic searches, including a range of database sources to ensure coverage of the literature. 
Screening, quality assessment and data extraction were carried out in accordance with clearly 
defined a priori criteria and tools. 
Most studies were carried out in the UK, and hence these should be broadly applicable to current UK 
practice, although detailed information on populations and contexts was usually lacking. The studies 
reflect some local variability in which groups were considered eligible for BCG (and, again, less than 
completely clear reporting), although this is unlikely to be a major barrier to applicability. 
The main limitations of this review relate to the quantity and quality of the primary evidence. As 
discussed in section 4.2 above, all the included studies except one received low quality ratings for 
internal validity. Several limitations are seen across the studies, relating particularly to study design 
(specifically the absence of control groups), the reporting of population characteristics and 
intervention content, and data analysis. In addition, as noted above, one specific issue not reflected 
in the QA tool is the confusion (and sometimes clear inconsistency) in how eligibility for BCG was 
evaluated and recorded. Since this affects the denominator of the fraction representing BCG 
coverage rates, it results in serious ambiguities in how the latter outcome variable should be 
interpreted in several studies.  
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7 Appendix 1. Search strategies 
# Database Hits 
1 Medline 1777 
2 Medline in Process 86 
3 PsycINFO 14 
4 Social Policy and Practice  12 
5 HMIC 50 
6 Embase 3527 
7 CINAHL 110 
8 British Nursing Index 24 
9 ASSIA 30 
10 ERIC 0 
11 NCJRS 0 
12 Sociological Abstracts 8 
13 The Cochrane Library 162 
14 Science Citation Abstracts 2367 
15 Conference Proceedings Citation 
Index 
5 
16 Open Grey 3 
17  British Education Index 0 
 Total 8175 
 - De-duplication -
2866 






Data Parameters:  1946 to June Week 3 2013 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,kw. 140658 
2 exp Tuberculosis/ 153696 
3 1 or 2 189102 
4 ("Bacille Calmette-Guerin" or "Bacillus Calmette-Guerin" or BCG).ti,ab,kw. 19611 
5 BCG Vaccine/ 16436 
6 or/4-5 24551 
7 (uptake or up-take or (up adj1 take) or takeup or take-up).ti,ab,kw. 241878 
8 ((increas$ or improv$ or inform$ or impact$ or encourag$ or enhanc$ or support$ or 955063 
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adopt$ or assist$) adj5 (demand or impact$ or respon$ or satisf$ or accept$ or 
respon$ or referr$ or self-referr$ or follow up or identification or identify$ or finding 
or compliance or comply or complie$ or adher$ or access$ or avail$ or provision or 
administrat$ or receiv$ or monitoring)).ti,ab,kw. 
9 
((increas$ or improv$ or impact$ or encourag$ or enhanc$ or support$ or adopt$ or 
assist$) adj3 (coverage or cover or target$ or receipt or particip$ or efficacy or 
effectiveness)).ti,ab,kw. 
90505 
10 exp Patient Acceptance of Health Care/ 159182 
11 exp Immunization/ 133754 
12 *Immunization Programs/ 4725 
13 or/7-12 1489125 
14 (promot$ or educat$).ti,ab,kw. 879473 
15 ((increas$ or improv$ or encourag$ or raising) adj3 awareness).ti,ab,kw. 15939 
16 
((advert$ or campaign or policy) adj5 (aware$ or increas$ or improv$ or encourag$ or 
support$ or involv$ or adopt$ or assist$ or promot$ or utilize or utilise or receive or 
optimiz$ or optimis$)).ti,ab,kw. 
14693 
17 
(e-mail or email or electronic mail or letter$ or invite or reminder$ or invitation$ or 
written or telephone or text or mobile or SMS or twitter or tweet or facebook or 
social media or social marketing or mass media or marketing or target$ or chat room$ 
or billboard or flyer or poster or hand out or leaflet$ or radio or television or TV or 
workshop$ or outreach or incentiv$).ti,ab,kw. 
1074401 
18 *Health education/ 29126 
19 *Health promotion/ 32482 
20 Mass Media/ 8600 
21 or/14-20 1874631 
22 exp Health Personnel/ 357655 
23 
((patient or person or doctor$ or physician$ or GP or general practi$ or hospital or 
nurse) and (vaccinat$ or Immunisation or vaccination or inoculation)).ti,ab,kw. 
13149 
24 ((health or healthcare) adj3 (worker$ or personnel or staff)).ti,ab,kw. 35028 
25 (medical adj3 (worker$ or personnel or staff)).ti,ab,kw. 16074 
26 (hospital adj3 (worker$ or personnel or staff or volunteer)).ti,ab,kw. 8647 
27 (Midwife or midwives or midwifery).ti,ab,kw. 14466 
28 (allied health adj3 (staff or worker$ or professional$ or personnel)).ti,ab,kw. 1343 
29 (lay health adj3 (staff or worker$ or professional$ or personnel)).ti,ab,kw. 152 
30 ((laboratory or lab) adj3 staff).ti,ab,kw. 945 
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31 (organisation or delivery or shortage$).ti,ab,kw. 276505 
32 (vet$1 or veterinary or veterinarian).ti,ab,kw. 29438 
33 (farm$1 or farmer$ or abattoir).ti,ab,kw. 37118 
34 student$.ti,ab,kw. 153942 
35 exp Delivery of Health Care/ 766701 
36 ((vaccination or inoculation or immunisation) and delivery).ti,ab,kw. 4097 
37 
(school$ or outreach or university or work or (out adj1 reach$) or (out adj2 hours) or 
mobile or home or communi$).ti,ab,kw. 
1374978 
38 ((peer or community) adj1 led).ti,ab,kw. 542 
39 




(free adj3 (vaccin$ or inoculat$ or immuni?$ or clinic or session or 
appointment$)).ti,ab,kw. 
2310 
41 ((vaccin$ or inoculat$ or immuni?$) adj3 clinic$).ti,ab,kw. 5566 
42 
(integrated adj3 (vaccin$ or inoculat$ or immuni?$ or clinic or session or 
appointment$ or healthcare or service or organisation)).ti,ab,kw. 
1701 
43 (screen$ or surveillance).ti,ab,kw. or *Mass Screening/ 510042 
44 or/22-43 2944452 
45 Randomized Controlled Trial.pt. 367158 
46 Trial.ti,ab. 328756 
47 effectiveness.ti. 54530 
48 or/45-47 606258 
49 13 or 21 or 44 5100971 
50 48 or 49 5480628 
51 3 and 6 and 50 4811 
52 exp animals/ not humans.sh. 3910958 
53 51 not 52 3818 
54 
(cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog 
or hedgehogs or mice or mouse or rat or rats).mp. 
2918597 
55 53 not 54 2823 




File Name: TB MEDLINE Endnote RIS.txt 
 




Database: Medline in Process 
Host: OVID 
Data Parameters: July 02, 2013 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,kw. 9151 
2 exp Tuberculosis/ 0 
3 1 or 2 9151 
4 ("Bacille Calmette-Guerin" or "Bacillus Calmette-Guerin" or BCG).ti,ab,kw. 644 
5 BCG Vaccine/ 0 
6 or/4-5 644 
7 (uptake or up-take or (up adj1 take) or takeup or take-up).ti,ab,kw. 12965 
8 
((increas$ or improv$ or inform$ or impact$ or encourag$ or enhanc$ or support$ or 
adopt$ or assist$) adj5 (demand or impact$ or respon$ or satisf$ or accept$ or respon$ 
or referr$ or self-referr$ or follow up or identification or identify$ or finding or 
compliance or comply or complie$ or adher$ or access$ or avail$ or provision or 
administrat$ or receiv$ or monitoring)).ti,ab,kw. 
76188 
9 
((increas$ or improv$ or impact$ or encourag$ or enhanc$ or support$ or adopt$ or 
assist$) adj3 (coverage or cover or target$ or receipt or particip$ or efficacy or 
effectiveness)).ti,ab,kw. 
7588 
10 exp Patient Acceptance of Health Care/ 0 
11 exp Immunization/ 0 
12 *Immunization Programs/ 0 
13 or/7-12 93277 
14 (promot$ or educat$).ti,ab,kw. 58425 
15 ((increas$ or improv$ or encourag$ or raising) adj3 awareness).ti,ab,kw. 1435 
16 
((advert$ or campaign or policy) adj5 (aware$ or increas$ or improv$ or encourag$ or 
support$ or involv$ or adopt$ or assist$ or promot$ or utilize or utilise or receive or 
optimiz$ or optimis$)).ti,ab,kw. 
1122 
17 
(e-mail or email or electronic mail or letter$ or invite or reminder$ or invitation$ or 
written or telephone or text or mobile or SMS or twitter or tweet or facebook or social 
media or social marketing or mass media or marketing or target$ or chat room$ or 
billboard or flyer or poster or hand out or leaflet$ or radio or television or TV or 
94355 
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workshop$ or outreach or incentiv$).ti,ab,kw. 
18 *Health education/ 0 
19 *Health promotion/ 0 
20 Mass Media/ 0 
21 or/14-20 145293 
22 exp Health Personnel/ 0 
23 
((patient or person or doctor$ or physician$ or GP or general practi$ or hospital or 
nurse) and (vaccinat$ or Immunisation or vaccination or inoculation)).ti,ab,kw. 
789 
24 ((health or healthcare) adj3 (worker$ or personnel or staff)).ti,ab,kw. 2549 
25 (medical adj3 (worker$ or personnel or staff)).ti,ab,kw. 793 
26 (hospital adj3 (worker$ or personnel or staff or volunteer)).ti,ab,kw. 413 
27 (Midwife or midwives or midwifery).ti,ab,kw. 1012 
28 (allied health adj3 (staff or worker$ or professional$ or personnel)).ti,ab,kw. 114 
29 (lay health adj3 (staff or worker$ or professional$ or personnel)).ti,ab,kw. 11 
30 ((laboratory or lab) adj3 staff).ti,ab,kw. 41 
31 (organisation or delivery or shortage$).ti,ab,kw. 18769 
32 (vet$1 or veterinary or veterinarian).ti,ab,kw. 2609 
33 (farm$1 or farmer$ or abattoir).ti,ab,kw. 3149 
34 student$.ti,ab,kw. 11392 
35 exp Delivery of Health Care/ 2 
36 ((vaccination or inoculation or immunisation) and delivery).ti,ab,kw. 282 
37 
(school$ or outreach or university or work or (out adj1 reach$) or (out adj2 hours) or 
mobile or home or communi$).ti,ab,kw. 
120077 
38 ((peer or community) adj1 led).ti,ab,kw. 49 
39 




(free adj3 (vaccin$ or inoculat$ or immuni?$ or clinic or session or 
appointment$)).ti,ab,kw. 
132 
41 ((vaccin$ or inoculat$ or immuni?$) adj3 clinic$).ti,ab,kw. 347 
42 
(integrated adj3 (vaccin$ or inoculat$ or immuni?$ or clinic or session or appointment$ 
or healthcare or service or organisation)).ti,ab,kw. 
144 
43 (screen$ or surveillance).ti,ab,kw. or *Mass Screening/ 35723 
44 or/22-43 178643 
45 Randomized Controlled Trial.pt. 700 
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46 Trial.ti,ab. 20486 
47 effectiveness.ti. 3306 
48 or/45-47 23620 
49 13 or 21 or 44 340855 
50 48 or 49 354036 
51 3 and 6 and 50 124 
52 exp animals/ not humans.sh. 5 
53 51 not 52 124 
54 
(cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
68371 
55 53 not 54 89 
56 limit 55 to yr="1993 -Current" 86 
 
Notes: N/A 





Data Parameters: 1806 to July Week 1 2013 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,sh. 2048 
2 ("Bacille Calmette-Guerin" or "Bacillus Calmette-Guerin" or BCG).ti,ab,sh. 63 
3 1 and 2 18 
4 
(cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
171166 
5 3 not 4 16 
6 limit 5 to yr="1993 -Current" 14 
 
Notes: N/A 
File Name: TB PsycINFO Endnote RIS.txt 
 
4. 
Database: Social Policy and Practice 
Host: OVID 
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Data Parameters: 201304 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,sh. 178 
2 ("Bacille Calmette-Guerin" or "Bacillus Calmette-Guerin" or BCG).ti,ab,sh. 21 
3 1 and 2 19 
4 
(cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
154 
5 3 not 4 19 
6 limit 5 to yr="1993 -Current" 12 
 
Notes: N/A 





Data Parameters: 1979 to March 2013 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,sh. 898 
2 ("Bacille Calmette-Guerin" or "Bacillus Calmette-Guerin" or BCG).ti,ab,sh. 113 
3 1 and 2 74 
4 
(cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats).mp. 
1022 
5 3 not 4 73 
6 limit 5 to yr="1993 -Current" 50 
 
Notes: N/A 
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Data Parameters: 1980 to 2013 Week 26 




# Searches Results 
1 (Tuberculosis or TB).ti,ab,kw. 158557 
2 exp Tuberculosis/ 179093 
3 1 or 2 219525 
4 ("Bacille Calmette-Guerin" or "Bacillus Calmette-Guerin" or BCG).ti,ab,kw. 21727 
5 BCG vaccine/ 27776 
6 4 or 5 34719 
7 (uptake or up-take or (up adj1 take) or takeup or take-up).ti,ab,kw. 287031 
8 
((increas$ or improv$ or inform$ or impact$ or encourag$ or enhanc$ or support$ or 
adopt$ or assist$) adj5 (demand or impact$ or respon$ or satisf$ or accept$ or 
respon$ or referr$ or self-referr$ or follow up or identification or identify$ or finding 
or compliance or comply or complie$ or adher$ or access$ or avail$ or provision or 
administrat$ or receiv$ or monitoring)).ti,ab,kw. 
1245048 
9 
((increas$ or improv$ or impact$ or encourag$ or enhanc$ or support$ or adopt$ or 
assist$) adj3 (coverage or cover or target$ or receipt or particip$ or efficacy or 
effectiveness)).ti,ab,kw. 
116738 
10 exp patient attitude/ 232066 
11 *preventive health service/ 10156 
12 7 or 8 or 9 or 10 or 11 1782539 
13 (promot$ or educat$).ti,ab,kw. 1064022 
14 ((increas$ or improv$ or encourag$ or raising) adj3 awareness).ti,ab,kw. 22130 
15 
((advert$ or campaign or policy) adj5 (aware$ or increas$ or improv$ or encourag$ or 
support$ or involv$ or adopt$ or assist$ or promot$ or utilize or utilise or receive or 
optimiz$ or optimis$)).ti,ab,kw. 
17582 
16 
(e-mail or email or electronic mail or letter$ or invite or reminder$ or invitation$ or 
written or telephone or text or mobile or SMS or twitter or tweet or facebook or 
social media or social marketing or mass media or marketing or target$ or chat room$ 
or billboard or flyer or poster or hand out or leaflet$ or radio or television or TV or 
workshop$ or outreach or incentiv$).ti,ab,kw. 
1418838 
17 *Health education/ 30630 
18 *Health promotion/ 28048 
19 exp mass communication/ 340542 
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20 13 or 14 or 15 or 16 or 17 or 18 or 19 2616185 
21 exp health care personnel/ 804028 
22 
((patient or person or doctor$ or physician$ or GP or general practi$ or hospital or 
nurse) and (vaccinat$ or Immunisation or vaccination or inoculation)).ti,ab,kw. 
18037 
23 ((health or healthcare) adj3 (worker$ or personnel or staff)).ti,ab,kw. 42013 
24 (medical adj3 (worker$ or personnel or staff)).ti,ab,kw. 20946 
25 (hospital adj3 (worker$ or personnel or staff or volunteer)).ti,ab,kw. 10684 
26 (Midwife or midwives or midwifery).ti,ab,kw. 15857 
27 (allied health adj3 (staff or worker$ or professional$ or personnel)).ti,ab,kw. 1820 
28 (lay health adj3 (staff or worker$ or professional$ or personnel)).ti,ab,kw. 164 
29 ((laboratory or lab) adj3 staff).ti,ab,kw. 1297 
30 (organisation or delivery or shortage$).ti,ab,kw. 360690 
31 (vet$1 or veterinary or veterinarian).ti,ab,kw. 36911 
32 (farm$1 or farmer$ or abattoir).ti,ab,kw. 42447 
33 student$.ti,ab,kw. 190996 
34 exp health care delivery/ 1752010 
35 ((vaccination or inoculation or immunisation) and delivery).ti,ab,kw. 5249 
36 
(school$ or outreach or university or work or (out adj1 reach$) or (out adj2 hours) or 
mobile or home or communi$).ti,ab,kw. 
1816391 
37 ((peer or community) adj1 led).ti,ab,kw. 674 
38 




(free adj3 (vaccin$ or inoculat$ or immuni?$ or clinic or session or 
appointment$)).ti,ab,kw. 
2636 
40 ((vaccin$ or inoculat$ or immuni?$) adj3 clinic$).ti,ab,kw. 6347 
41 
(integrated adj3 (vaccin$ or inoculat$ or immuni?$ or clinic or session or 
appointment$ or healthcare or service or organisation)).ti,ab,kw. 
2241 
42 (screen$ or surveillance).ti,ab,kw. or *Mass Screening/ 662857 
43 or/21-42 4687449 
44 randomized controlled trial/ 345100 
45 Trial.ti,ab. 426818 
46 effectiveness.ti. 68922 
47 44 or 45 or 46 696424 
48 12 or 20 or 43 7346108 
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49 47 or 48 7706249 
50 3 and 6 and 49 6128 
51 exp animal/ not exp human/ 3939260 
52 50 not 51 5434 
53 
(cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog 
or hedgehogs or mice or mouse or rat or rats).mp. 
3067423 
54 52 not 53 4444 
55 limit 54 to yr="1993 -Current" 3527 
 
Notes: N/A 




Host: Ebsco Host 
Data Parameters:  1937-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 110 
Strategy: 
((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
Notes: Search limited by date (1993-Current). A server side de-duplication was undertaken to 
remove MEDLINE hits 
File Name: TB CINAHL Endnote RIS.txt 
 
8. 
Database: British Nursing Index (BNI) 
Host: ProQuest 
Data Parameters: 1994-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 24 
Strategy: 
((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
 
Notes: N/A 





Data Parameters: 1987-Current 
Date Searched: Wednesday July 3rd 2013 





((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
Notes: Search limited by date (1993-Current) 





Data Parameters: 1966-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 0 
Strategy: 
((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
Notes: N/A 





Data Parameters: 1975-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 0 
Strategy: 
((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
Notes: N/A 
File Name: N/A 
 
12. 
Database: Sociological Abstracts  
Host: ProQuest 
Data Parameters: 1952-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 8 
Strategy: 
((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
Notes: N/A 
File Name: TB Soc Abs Endnote RIS.txt 
 
13. 
Database: The Cochrane Library 
Host: http://www.thecochranelibrary.com/view/0/index.html 
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Data Parameters:  CENTRAL 6 of 12 (June 2013) CDSR, DARE, NHS EEDS and HTA issue 2 of 4 April.  
Date Searched: Wednesday July 3rd 2013 
Hits: CDSR: 9; DARE 8;  CENTRAL 114; METHODS 2; HTA 4. (Total 162) 
Strategy: 
ID Search Hits 
#1 (Tuberculosis or TB):ti,ab,kw  (Word variations have been searched) 2813 
#2 MeSH descriptor: [Tuberculosis] explode all trees 1507 
#3 #1 or #2  2820 
#4 (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)  1250 
#5 MeSH descriptor: [BCG Vaccine] this term only 660 
#6 #4 or #5  1250 
#7 #3 and #6 from 1993 to 2013 162 
 
Notes: N/A 
File Name: TB Cochrane Endnote RIS.txt 
 
14. 
Database:  Science Citation Index Expanded (SCI-EXPANDED) & Social Sciences Citation Index (SSCI) 
Host: ISI 
Data Parameters: 1900 & 1956 - Current  
Date Searched: Wednesday July 3rd 2013 
Hits: 2367 
Strategy: 
Topic=(((Tuberculosis) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG))) 
NOT Topic=((cow or cows or cattle or bovine or bovis or calves or badger or badgers or hedgehog or 
hedgehogs or mice or mouse or rat or rats)) 
 
Notes: N/A 
File Name: TB WOS Endnote RIS.txt 
 
15. 
Database: Conference Proceedings Citation Index- Science (CPCI-S) & Conference Proceedings 
Citation Index- Social Science & Humanities (CPCI-SSH) 
Host: ISI 
Data Parameters: 1990-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 5 
Strategy: Wednesday July 3rd 2013 
Topic=(((Tuberculosis) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG))) 
 
Notes: This search was date limited 2011-Current 
File Name: TB ISI Conference Abs Endnote RIS.txt 
 
16. 
Database: Open Grey 




Date Searched: Wednesday July 3rd 2013 
Hits: 3 
Strategy: 
(Tuberculosis) AND (BCG) 
 
Notes: N/A 
File Name: TB Grey Endnote RIS.txt 
 
17. 
Database: British Education Index  
Host: ProQuest 
Data Parameters: 1994-Current 
Date Searched: Wednesday July 3rd 2013 
Hits: 0 
Strategy: 
((Tuberculosis or TB) AND (("Bacille Calmette-Guerin") or ("Bacillus Calmette-Guerin") or BCG)) 
Notes: N/A 
File Name: N/A 
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8 Appendix 2. Evidence tables 


























Aim of study: 
To evaluate 
the efficacy of 
a revised 
Source population/s: 
Contact tracing clinic in 
South Glamorgan 
Eligible population: 
Recruitment: not applicable 
(retrospective  case record 
study) 
Selected population: 
Contact of someone 
identified to have TB within 
South Glamorgan 
Excluded population: Not 
reported 
Sample characteristics: No 
information on study 
sample. In broader 
population: South 
Glamorgan population of 
408,600 (95.2% whites, 
1.9% of Indian subcontinent 
origin, 0.5% black Africans); 
low TB incidence area, 103 
index cases of TB over 3 
year period; 1987-1989 TB 




‘simplified’ protocol for 
TB contact screening 
(Figure1, p.1128), 
previous protocol not 
described in any detail 




Sample sizes: Pre-test: 
611 for old protocol; 
Post-test: 732 for new 
protocol 
Baseline comparisons: 
Not applicable  
Study sufficiently 
powered? Not reported 
 
Outcomes: Primary 
of interest: number 













Results for all relevant 
outcomes: BCG given: 
previous protocol 119 
persons or 20% (all given it 
appropriately); current 
protocol 161 persons or 
22% (95% given it 
appropriately and 5% 
inappropriately) and 5 
failed to attend for 
vaccination (0.7%) and 1 
refused (0.1%). 
Inappropriately omitted: 
previous protocol 38 
persons or 6.4%; current 
protocol 2 persons or 0.3%. 
Results on inequalities: 
Not reported, but 
approximately half the 
index cases were from 
ethnic minority 
backgrounds  
Total sample: Baseline: 611 
Endpoint: 732 
Attrition details: Not 
Limitations identified 
by author: Not reported 
Limitations identified 
by review team: Non-
comparative design. 
Poorly reported time 
frame. Somewhat 
limited information on 
population. Study is not 
focused on our review 
question, just happens 
to report relevant BCG 
data. Previous protocol 
not described. 
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
Source of funding: Not 
reported 
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S. & Mactier, 
H., 2006. 
Implementing 
the new BCG 
vaccination 












Aim of study: 
To describe 
Source population/s: (out-
patient) BCG clinic at 
Princess Royal Maternity 
(PRM) in Glasgow 
Eligible population: 
Recruitment: mothers 
whose infants were eligible 
for BCG were given verbal 
explanation of BCG policy 
before discharged from 
hospital after giving birth; 
women who agreed to have 
child immunised given 




Women with infants at 
higher risk of TB and 
delivering at Princess Royal 
Maternity 
Excluded population: Not 
reported 
Sample characteristics: No 
information on study 
sample. Hospital in 




project: junior medical 
staff individually 
advised of indications 
for BCG immunization 
and encouraged to 
identify / offer 
immunization to infants 




immunization and given 
details of a clinic 
appointment by letter, 
telephone or via her 
Health Visitor. 
Full intervention: "clear 
guidelines for infants at 
risk of TB made 
available to the 
postnatal ward staff, 
verbal explanation of 
the BCG immunization 
policy given to mother 
Outcomes: BCG 
immunisation rate 
Follow up periods: 
Baseline: (data 
from local audit) 
April 2002 – March 
2003 ; Pilot project 
carried out March-





- post-test data 







Results for all relevant 
outcomes: Baseline (April 
2002 to March 2003) 5 
infants received BCG 
immunization prior to 
discharge from the 
postnatal ward, number of 
infants eligible for BCG 
vaccination not reported; 
Pilot study (March-June 
2003) 39 infants identified 




December 2004) 606 
infants identified as eligible 
for BCG vaccination, 93% 
immunised 
Results on inequalities: not 
reported, but those at 
high-risk for TB include 
BME populations 
Total sample: 5,200 births 
at Princess Royal Maternity 
per annum, on average 
Pilot: 39 infants eligible for 
Limitations identified 
by author: Audit does 
not determine how 
many eligible infants 
failed to be identified in 
the maternity hospital. 
Maternity case records 
provide some data 
regarding maternal 
ethnicity, but paternal 
ethnicity, family history 
of TB and intended 













Number of infants 
eligible for BCG (and so 
coverage rate) at pre-
















deprived area with a large 
immigrant and asylum-
seeking population; has 
approximately 5,200 
deliveries per year. 
 
at routine pre-discharge 
baby examination, if she 
agrees to immunization 
handwritten 
appointment card for 
next BCG clinic given 
immediately, with a 








Sample sizes: 5,200 
births at Princess Royal 
Maternity per annum, 
on average 
Pilot: 39 infants eligible 
for BCG vaccination 
Full intervention: 606 
infants identified as 
eligible for BCG 
vaccination (over 18 
months) 
Baseline comparisons: 
Not applicable   
Study sufficiently 
BCG vaccination 
Full intervention: 606 
infants identified as eligible 
for BCG vaccination (over 
18 months) 
Attrition details: Not 
applicable 
 
test not reported.  
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
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Aim of study: 







District hospital in Milton 
Keynes 
Eligible population: 
Recruitment: not applicable 
(retrospective case record 
study), assume all women 
giving birth in selected 
hospital eligible in principle   
Selected population: 
Implicitly, all births to 
minority ethnic parents in 
selected site 
Excluded population:  Not 
reported 
Sample characteristics: No 
information on study 
sample. Population of 
Milton Keyes 190,000, 
approximately 3000 
deliveries a year, nearly all 
in the district hospital, 5.4% 
of population were in 
ethnic groups other than 
white  
Method of allocation: 
Not applicable  
Intervention/s 
description:  1991 
installed a computer in 
the obstetric 
department at the 
Milton Keynes district 
hospital so staff could 
enter whether neonate 
was likely to be in a 
higher-risk group; if 
neonate was in high-risk 
group a form requesting 
BCG vaccination was 
automatically printed 
out, staff to provide the 
BCG vaccination and  
return form to 
community child health 
department where it 
was entered their 
computer; if baby not 
vaccinated then mother 
offered appointment to 








divided by eligible 
population, 
although this is 
defined differently 
at different time 
points) 
Follow up periods: 







statistics, with 95% 
CIs 
 
Results for all relevant 
outcomes: 1988 (pre) 42 
vaccinations given, 23.9% 
coverage (95% CI 17.7%-
30.3%); 1989 (pre) 31 
vaccinations given, 18.3% 
coverage (12.5%-24.2%); 
1990 (pre) 33 vaccinations 
given, 19.3% coverage 
(13.4%-25.2%); 1992 (post) 
-234 vaccinations given, 
52.6% coverage (47.9%-
57.2%); 1993 (post) 354 
vaccinations given, 77.5% 
coverage (73.6%-81.3%) 
Total sample: Not reported 
as such, somewhere under 
3,000 births per year 
Results on inequalities: 
Population of study as a 
whole is BME people, 
although not totally clear 
how defined 




by author: Not reported 
Limitations identified 
by review team: Non-
comparative, 
retrospective design. 
Very little information 
on methods or context 
(and what is reported is 
sometimes unclear). 
Because pre and post 
outcome measures are 
calculated differently, 
the quantitative findings 
cannot be regarded as 
meaningful. 
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
Source of funding: Not 
reported. 
 





monitoring   
Study design: 









Sample sizes: Hard to 
define due to 
retrospective nature of 
study. Milton Keynes 
has about 3000 
deliveries a year, nearly 
all in the district 
hospital and authors' 
estimates of eligible 
population range from 
169-457 per year 
(problematic estimates). 
Baseline comparisons: 
Not applicable  
Study sufficiently 
powered? Not reported 
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e Disease & 
Public 
Health.1(4), 
281-282.   
Country of 
study: UK 
Aim of study: 
To describe 
the impact of 
a new local 
policy on BCG 
Study design: 
BA (or ITS; 4 
Source population/s: 
Antenatal clinic and 




questionnaires given in all 
new birth packs and 
distributed to health 
visitors by the community 
trust's health department 
Selected population:  
Implicitly, all giving birth in 
selected hospitals (data 
collected from health 
visitors.) Response rates : 
response rates: 96%, 98%, 
93%, 87%. 
Excluded population: Not 
reported 
Sample characteristics: No 
information on study 
sample. Bolton: population: 
270,000, 8% ethnic 
minorities (largely from 
Indian subcontinent), 





vaccination moved from 
community medical 
officers to midwives and 
health visitors. Training 
sessions for midwives 
and health visitors on 
tuberculosis, advice 
about the vaccination, 
percutaneous 





midwives and nurses 
receive certificate of 
attendance and copy of 
the neonatal 
vaccination policy. 
Women whose infant 
indicated for BCG were 
identified by midwife at 
first visit to antenatal 
clinic and given 
Outcomes: Primary 
of interest: number 
of children for 
whom BCG was 
indicated and had 
been given it within 
the first three 
months of life 
Follow up periods: 
1 year increments: 
1993 (pre-
intervention); 








Results for all relevant 
outcomes: Infants for 
whom BCG was indicated 
who received it by 3 
months (sig NR): 1993 (pre-
intervention) 6% ;1994 
88%, 1995 90%, 1996 89% 
(post-intervention) 
Results on inequalities: not 
explicitly discussed, but 
policy targeted those born 
to parents from Indian 
subcontinent 
Total sample: Baseline: 
576; Year 2: 590; Year 3: 
555; Year 4: 521 




by author: Not reported 
Limitations identified 
by review team: Non-
comparative design. 
Significance of findings 
not reported. Limited 
detail on characteristics 
of included population 
and healthcare workers. 
Data collection and 
measures unclear. 
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
Source of funding: Not 
reported 
 









between 2/3s and 3/4s of 
TB cases in Bolton are in 
people from Indian 
subcontinent, incidence of 
TB in persons from Indian 
subcontinent is 40 times 
higher than in white British 
persons, approximately 
3,500 babies born per year 
and approximately 20% of 
them eligible for BCG 
vaccination. 
 
information about BCG 
vaccination (verbally 
and in mother 
language); at 
subsequent visits before 
birth women given 
more information and 
asked to give consent 
for vaccination (to be 
done on maternity unit 
after birth or within 3 
months by a health 
visitor and after that at 
the Department of 





Sample sizes:  Baseline: 
576 
Total: 2,242 across 4 
time points 
Baseline comparisons: 
Not applicable  
Study sufficiently 
powered? Not reported 
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Aim of study: 
To evaluate a 
programme 
Source population/s: 
Primary care in Hackney, 
London 
Eligible population: 
Recruitment (at practice 
level) all but one practice in 
Hackney were invited to 
participate (the other one 
was a pilot for the study). 
Recruitment by 
researchers, by letter. 
Individual patients were 
recruited on an opt-out 
basis, i.e. they were shown 
information about the 
study by practice 
receptionists, and were 
assumed to consent to 
participation if they did not 
object. 96% of eligible 
practices agreed to 
participate; participation 
numbers not reported for 
individual patients  
Selected population: Newly 
registered patients with all 
GP practices in Hackney 
Method of allocation: 
Cluster randomised by 
GP practice (N=50). 
Randomisation used a 
minimization method 
with respect to several 
aspects of the practice.   
Intervention/s 
description: Educational 
visits to practices by a 
specialist nurse and GP 
to promote TB 
screening and raise 
awareness of relevant 
guidelines, with follow-
up phone call 
(educational 
programme based on 
social influence theory). 
Incorporation of 
reminders into practice 
computer systems. 
Provision of equipment 
for TB testing. 
Telephone support from 
specialist nurse. 
Financial incentives to 
practices for TB tests 
Outcomes: Primary 
of interest: BCG 
coverage in people 
5 years or older 
(taken from 
practice records - 
unclear if this 





Follow up periods: 
Unclear; data were 
collected from June 
2002 - Sept 2004, 
but timing of 
intervention 
implementation 
with respect to this 





adjusted for cluster 
randomisation 
Results for all relevant 
outcomes: BCG coverage 
over study period 26.8 per 
1000 intervention, 3.8 per 
1000 control; odds ratio 
9.52 (95% CI 4.0–22.7). 
Results on inequalities: not 
reported, but population 
was ethnically mixed and 
low-SES 
Total sample: Baseline: 
N=50 practices; End point: 
N=48 practices (of which 
N=43 reported BCG data) 
Intervention group(s): 
Baseline: N=25 practices; 
Endpoint: N=25 practices, 
N=44,986 patients 
Control group(s): 
Baseline: N=25 practices; 
Endpoint: N=23 practices, 
N=48,984 patients 
Attrition details: 2 
practices merged in the 
study period. BCG data 
Limitations identified 
by author: Insufficient 
power to measure 
impact on proportion of 
cases identified, rather 
than changes in 
identification rate. Not 
everyone registers in 
primary care or attends 
health checks. 
Limitations identified 
by review team: 
Methodologically robust 
study. Some minor 
flaws in reporting 
(follow-up time, 
definition of BCG 
coverage outcome). 




using more effective 
means of testing; 
evaluate effectiveness 
and cost-effectiveness 
of programmes with 
different types of 














Excluded population: None 
Sample characteristics: 
Mean age intervention (I) 
29, control (C) 26; I male 
47%, C 46%; I 45% white, 
22% black, 9% Asian, C 42% 
white, 24% black, 10% 
Asian; I N=248 mean 
immigrants per practice, C 
N=272. 
 
(£7 each).  
Control/comparison/s 
description: Usual care 
Sample size at baseline: 
N =50 practices, 
N=93,970 patients 
Baseline comparisons: 
Checked for differences 
at practice level in 
terms of: number of 
doctors; % patients 
attending registration 
checks; practices 
registering new patients 
at trial outset (open 
lists); practice nurse; 
whether approved for 
training doctors; 
whether had an EMIS 
computer system; list 
size; N of patients; 
ethnicity of patients; N 
of new immigrants 
registering; rank of 
multiple deprivation 
[unclear how 
measured]; sex of 
patients; age of 
patients.  
Study sufficiently 




settings and targeted 
populations. 
Source of funding: UK 
Department of Health 
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Aim of study: 
To describe 






Source population/s: Child 
health centres in Sweden 
Eligible population: 
Recruitment: not applicable 
(surveillance data) 
Selected population: All 
newborns in Sweden 
Excluded population: None 
Sample characteristics: No 
information on study 
sample. For population as a 
whole, 12% foreign born, 
3.7% from Africa or Asia 
(2004 figures).  
 
 
Method of allocation: 
Not applicable  
Intervention/s 
description: Nurses at 
child health centres 
given more information 
and education about 
the reasons for the 
change to selective 
vaccination, and in 
particular, about the 
case definition for risk 




Sample sizes: Annual 
number of births 90,000 
to 124,000  
Baseline comparisons: 
Not applicable  
Study sufficiently 



















Results for all relevant 
outcomes: Incomplete 
reporting. Cohorts born in 
first five-year period (1976-
1981) following change in 
BCG policy vaccination 
coverage of newborns fell 
from at least 95% (before 
1975) to below 2%; 1982 
onwards gradual increase 
of vaccination coverage 
reaching levels above 15%, 
among cohorts born in 
1998 and later; BCG 
coverage of children in the 
defined risk groups was 
estimated at about 88% 
among children born 
during the period 1998 to 
2002. 
Results on inequalities: not 
reported 
Total sample: Not reported 




by author: Not reported 
Limitations identified 
by review team:  Non-
comparative design. 
Study is not 
conceptualized as an 
outcome evaluation (it 
can be interpreted as 
such, but this is 
problematic.) Very 
limited reporting on any 
dimension, including 
results and intervention 
content. 
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
Source of funding: Not 
reported 
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Nesbitt, A. & 
O'Sullivan, D., 















Aim of study: 
To audit the 
implementati
on of BCG 
Source population/s: 
Primary care; health visiting 




Recruitment: by medical 
officers for pre-test and by 
health visitors for post-test 
(not clearly stated; limited 
information overall.) 
Response rates 81% pre, 
86% post, although unclear 




Implicitly, all infants born in 
selected area 
Excluded population: Not 
reported 
Sample characteristics: No 
information on study 
sample other than whether 
they met BCG eligibility 
criteria (Table 3). In source 




what formed part of the 
standard policy (at pre-
test) and what was 




control met with clinical 
directorates of acute 
hospitals to encourage 
them to improve the 
availability of BCG to 
neonates at risk. Health 
visitors trained to 
identify and refer 
eligible infants to 
designated local clinics 
where BCG vaccination 
is offered, and leaflets 
about BCG for parents 












two time points, 
but timing of 
intervention 
relative to these (or 






statistics and odds 
ratio with 95% CI 
 
Results for all relevant 
outcomes: Pre 11% (36 of 
342 eligible); post 14% (30 
of 210). Analysis by site 
shows most of this to be 
accounted for by one of 
the four sites. "[T]he 
difference was not 
statistically significant 
(odds ratio=0.6; 95% 
confidence interval 0.34-
1.07)"; this appears to be 
incorrect. 
Results on inequalities: not 
reported, but most infants 
eligible for BCG (88% at 
baseline) were eligible by 
being born outside of 
Europe / North America / 
Australia / NZ / Japan. 
Total sample: Baseline: 
804; 
Endpoint: 527 




by author: Not reported 
as such, authors report 
as a process finding that 
applying BCG eligibility 
criteria may not be 
reliable - this would also 
be a limitation of the 
data. 
Limitations identified 
by review team: Non-
comparative design. 
Unclarity in definition 
and timing of 
intervention. Limited 
information on 
participants or context. 
Apparent error in 
reporting findings. 
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
Source of funding: Not 
reported 
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population: 26% of 
population and 42% of 0-
4yo children were of non-
White ethnicity; TB 
notification rate of 32 per 
100,000, highest in people 





Sample sizes: Baseline: 
804;  Total: 1,604 over 




powered? Not reported 
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M., et al., 
2008. 
Effectiveness 

















Primary health centres in 
Isparta, Turkey 
Eligible population:  
Recruitment of healthcare 
workers : those in primary 
health centres were invited 
to participate (unclear how, 
and if this was all of them) ;  
For population vaccinated: 
presume from record 
review, so not applicable 
Selected population:  
Healthcare workers: people 
with responsibility for 
providing vaccination 
within primary care, if all 
were invited 18% 
participated; Population 
vaccinated: implicitly, all 
children <1yo 
Excluded population:  Not 
reported 
Sample characteristics:  
Limited information on 
population receiving 





workshops (3 full days) 
were conducted that 
comprised instructive 
lectures, activities 




The workshop content 
included vaccines, 
national vaccination 
schedule, cold chain and 
management, planning 
and regulation of 
immunization, tracking 
the trends and increase 





materials provided by 
the MoH for EPI training 




coverage for BCG, 
(also hepatitis B 
and DTP/OPV, not 
extracted here) 












Results for all relevant 
outcomes: Pre-test: 
N=1,287 vaccinations 
carried out; 25.4% 
coverage; Post-test: 
N=1,294 vaccinations 
carried out; 25.8% 
coverage. Study authors 
report that this is 
significant at p<0.001 
(seems questionable.) 
Results on inequalities: not 
reported 
Total sample: Baseline: 
N=229 HCWs, N=5,057 
children eligible for 
vaccination; Endpoint: 
unclear for HCWs, N=5,020 
children eligible for 
vaccination 
Attrition details: Not 
clearly reported for HCWs; 
not applicable for children  
 
Limitations identified 
by author: Duration of 
the intervention 
[unclear what this 
means; intervention 
may not be feasible in 
all settings?]. No results 
on cost-effectiveness. 
Findings may not be 





by review team: Non-
comparative design. 
Limited information on 
population receiving 
vaccination. Some 
unclarities in analysis. 
Main focus of analysis is 
knowledge and 
attitudinal outcomes, 
and changes in 
coverage rates are 
addressed only in 
passing; effect size in 
the latter is extremely 
small (and p-value 
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vaccination, either in study 
sample or in broader 
context. Healthcare 
workers: N=89 GPs, N=14 
nurses, N=88 midwives, 
N=38 health officers; mean 
age 31, mean years 






Sample sizes: Baseline: 
N=229 HCWs; N=5,057 
children eligible for 
vaccination ; Total 
sample size: N=10,077 
children eligible for 
vaccination across 2 
time points 
Baseline comparisons: 
Not applicable  
Study sufficiently 
powered? Not reported 
 
reported is implausible). 
Evidence gaps and/or 
recommendations for 
future research: Not 
reported 
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9 Appendix 3. Call for evidence 
Stakeholder 
Organisation  
Full Reference Inclusion/Exclusion 
Central Manchester 
University Hospitals NHS 
Foundation Trust  
Vaccines in Practice. December 2012. 
Volume 5, Issue 3. 
www.vaccinesinpractice.co.uk 
EX2: BCG vaccination not 
measured as an outcome 
London TB 
Commissioning Board 
Altass, L., Minnion, L., and Farran, S., 
2013. Report on BCG policy and provision 
in London, February 2013. National 
Health Service: London Health 
Programmes.  
EX1: report is not an 
outcome evaluation of an 
intervention  
North Bristol NHS Trust Van Tongeren, L., Nolan, S., Cook, V.J., 
FitzGerald, J.M., and Johnston, JC., 2013. 
Therapeutic drug monitoring in the 
treatment of tuberculosis: a retrospective 
analysis. Int J Tuberc Lung Dis.17(2),221-
4.  
Not relevant to this review 
Royal College of General 
Practitioners 
Lutge, E.E., Wiysonge, C.S., Knight, S.E., 
and Volmink, J., 2012. Material incentives 
and enablers in the management of 
tuberculosis. The Cochrane Library, 1.  
Not relevant to this review 
Royal College of General 
Practitioners 
M’Imunya, J.M., Kredo, T., and Volmink, 
J., 2012. Patient education and 
counselling for promoting adherence to 
treatment for tuberculosis. The Cochrane 
Library, 5. 
Not relevant to this review 
Royal College of General 
Practitioners 
Gallardo, C.R., Rigau Comas, D., 
Valderrama Rodríguez, A., Roqué i Figuls, 
M., Parker, L.A., Caylà, J., and Bonfill 
Cosp, X., 2012.  Fixed-dose combinations 
of drugs versus single drug formulations 
for treating pulmonary tuberculosis. The 
Cochrane Library, 5. 
Not relevant to this review 
Royal College of General 
Practitioners 
Steingart, K.R., Sohn, H., Schiller, I., Kloda, 
L.A., Boehme, C.C., Pai, M., and 
Dendukuri, N., 2013. Xpert® MTB/RIF 
assay for pulmonary tuberculosis and 
rifampicin resistance in adults. The 
Cochrane Library, 1. 
Not relevant to this review 
Royal College of General 
Practitioners 
Sharma, S.K., Sharma, A., Kadhiravan, T., 
and Tharyan, P., 2013. Rifamycins 
(rifampicin, rifabutin and rifapentine) 
compared to isoniazid for preventing 
tuberculosis in HIV-negative people at 
risk of active TB. The Cochrane Library, 7. 
Not relevant to this review 
Royal College of General 
Practitioners 
Adamu, B., Abdu, A., Abba, A.A., Borodo, 
M.M., and Tleyjeh, I.M., 2010. Antibiotic 
prophylaxis for preventing post solid 
organ transplant tuberculosis. The 
Cochrane Library, 7. 
Not relevant to this review 
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Royal College of General 
Practitioners 
Sinclair, D., Abba, K., Grobler, L., and 
Sudarsanam, T.D., 2011. Nutritional 
supplements for people being treated for 
active tuberculosis. The Cochrane Library, 
11.  
Not relevant to this review 
Royal College of General 
Practitioners 
Ziganshina, L.E., Titarenko, A.F., and 
Davies G.R., 2013. Fluoroquinolones for 
treating tuberculosis (presumed drug-
sensitive). The Cochrane Library, 6.  
Not relevant to this review 
Royal College of General 
Practitioners 
Arentz, M., Horne, D.J., and Walson, J.L. , 
2011. Treatment of drug-resistant 
tuberculosis in patients with HIV-1 
infection. The Cochrane Library, 12. 
Not relevant to this review 
Royal College of General 
Practitioners 
Rosa, B., Cavalcanti, R.V.,  Alves da 
Cunha, A.J.L,  Fernandes de Paulo, R.,  
Medronho, R.A., and Atallah, A.N., 2012. 
TMC207 for treatment of people with 
pulmonary tuberculosis. The Cochrane 
Library, 10. 
Not relevant to this review 
Royal College of General 
Practitioners 
Fox, G.J., Dobler, C.C., and Marks, G.B., 
2011. Active case finding in contacts of 
people with tuberculosis. The Cochrane 
Library, 9. 
Not relevant to this review 
Royal College of General 
Practitioners 
Marrone, M., Venkataramanan, V., 
Goodman, M., and Mase, S., 2011.  
Surgical interventions for treating 
multidrug and extensively-drug resistant 
pulmonary tuberculosis. The Cochrane 
Library, 2. 
Not relevant to this review 
Royal College of General 
Practitioners 
Royce, S., Anglemyer, A., Horvath, T., 
McCarthy, E., Rutherford, G., Baggaley, 
R., Suthar, A., and Negussie, E., 2013.  
Tuberculosis clinics providing or referring 
for antiretroviral therapy (protocol).  
PROSPERO 2013:CRD42013004238. 
Not relevant to this review 
Royal College of General 
Practitioners 
Mulder, C., Erkens, C.G.M.,  Kouw, P.M.,  
Huisman, E.M., Meijer, V., Wieneke, M.V., 
Borgdorff, M.W., and, van Leth, F., 2012. 
Missed opportunities in tuberculosis 
control in The Netherlands due to 
prioritization of contact investigations. 
European Journal of Public Health. 22(2), 
177-182.  
EX1: report is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
Nicol, M.P., Workman, L., Isaacs, W., 
Munro, J., and Black, F., 2011. Accuracy 
of the Xpert MTB/RIF test for the 
diagnosis of pulmonary tuberculosis in 
children admitted to hospital in Cape 
Town, South Africa: a descriptive study 
Lancet Infectious Diseases. 11(11), 819-
824.  
Not relevant to this review 
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Royal College of General 
Practitioners 
Department of Health., 2011.  
Tuberculosis: the disease, its treatment 
and prevention. London: Department of 
Health.  
EX1: leaflet is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
van Rie, A., Westreich, D.,  and Sanne, I., 
2011. Tuberculosis in patients receiving 
antiretroviral treatment: incidence, risk 
factors and prevention strategies. Journal 
of Acquired Immune Deficiency 
Syndromes. 56(4), 349-355.  
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
Basu, S., Stuckler, D., Bitton, A., Glantz, S, 
A., 2011. Projected effects of tobacco 
smoking on worldwide tuberculosis 
control: mathematical modelling analysis.   
British Medical Journal. 343(d5506).  
Not relevant to this review 
Royal College of General 
Practitioners 
Glaziou, P., Floyd, K., Korenromp, E.L., 
and Sismanidis, C., 2011. Lives saved by 
tuberculosis control and prospects for 
achieving the 2015 global target for 
reducing tuberculosis mortality. Bulletin 
of the World Health Organization. 89(8): 
573-582.  
EX2: BCG vaccination not 
measured as an outcome 
Royal College of General 
Practitioners 
Bothamley, G.H., Kruijshaar, M.E., and 
Kunst, H., 2011. Tuberculosis in UK cities: 
workload and effectiveness of 
tuberculosis control programmes. BMC 
Public Health. 11(896).   
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
Cayla, J.A., and Orcau, A., 2011. The 
control of tuberculosis in large cities in 
developed countries: an organisational 
problem. BMC Medicine. 127.   
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
Malmborg, R., Mann, G., and Squire, S.B., 
2011. Systematic assessment of the 
concept and practice of public-private 
mix for tuberculosis care and control. 
International Journal for Equity in Health 
2011. 10(49).  
EX2: BCG vaccination not 
measured as an outcome 
Royal College of General 
Practitioners 
World Health Organisation., 2011.  
Collaborative framework for care and 
control of tuberculosis and diabetes. 
Geneva: World Health Organisation.  
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
World Health Organisation., 2011. Global 
tuberculosis control 2011. Geneva: World 
Health Organisation. 
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
Abubakar, I., Lipman, M., Anderson, C., 
Davies, P., and Zumla, A., 2011. 
Tuberculosis in the UK: time to regain 
control.  BMJ. 343(7818):293-296.  
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
le Polain, O., Maguire, H., and Pedrazzoli, 
D. Unpublished. Epidemiology of TB in 
children in London, 2009 – 2011. Are 
Full text irretrievable  
NICE: Improving uptake of BCG for TB: Final report  
 
56 
opportunities for prevention being 
missed? London: Health Protection 
Agency.  
Royal College of General 
Practitioners 
Nguipdop-Djomo, P., Mangtani, P., 
Pedrazzoli, D., Rodrigues, L.C., and 
Abubakar, I., 2013. Uptake of neonatal 
BCG vaccination in England: performance 
of the current policy recommendations. 
Thorax. 0:1-3. 
EX1: study is not an 
outcome evaluation of an 
intervention 
Royal College of General 
Practitioners 
Pilger, D., Nguipdop-Djomo, P., Abubakar, 
I., Elliman, D., Rodrigues, L.C., Watson, 
J.M., Eastman, V., and Mangtani, P., 
2012. BCG vaccination in England since 
2005: a survey of policy and practice. BMJ 
Open. 2:e001303.  
EX1: study is not an 
outcome evaluation of an 
intervention 
TB Alert Patient Information Forum (PiF)., 2013. 
Making the Case for Information: the 
evidence for investing in high quality 
health information for patients and the 
public. London: Patient Information 
Forum.  
EX1: study is not an 
outcome evaluation of an 
intervention 
TB Alert Craig, G.M., Booth, H., Story, A., 
Hayward, A., Hall, J., Goodburn, A. and 
Zumla, A., 2007. The impact of social 
factors on tuberculosis management.   
Journal of Advanced Nursing. 58(5):418-
424. 
EX1: study is not an 
outcome evaluation of an 
intervention 
TB Alert Wanless, D., 2004. Securing good health 
for the whole population-final report.  
London: HMG Stationary Office.  
EX1: study is not an 
outcome evaluation of an 
intervention 
TB Alert Akugizibwe, P. and Ramakant, B., 2010. 
Challenges for community role in 
tuberculosis response. The Lancet. 
375(9731):2059-2061. 
EX1: study is not an 
outcome evaluation of an 
intervention 
TB Alert Basri, C., Bergström, K., Walton, W., 
Surya, A., Voskens, J., and Metha, F., 
2009. Sustainable scaling up of good 
quality health worker education for 
tuberculosis control in Indonesia: a case 
study. Human Resources for Health. 7:85. 
EX2: BCG vaccination not 
measured as an outcome 
TB Alert Whitehead, M., 2007. A typology of 
actions to tackle social inequalities in 
health. J Epidemiol Community Health. 
61(6), 473–478. 
EX1: study is not an 
outcome evaluation of an 
intervention 
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10 Appendix 4. Quality appraisal example 
Checklist items are worded so that 1 of 5 responses is possible: 
++ Indicates that for that particular aspect of study design, the study has been 
designed or conducted in such a way as to minimise the risk of bias. 
+ Indicates that either the answer to the checklist question is not clear from the 
way the study is reported, or that the study may not have addressed all 
potential sources of bias for that particular aspect of study design. 
− Should be reserved for those aspects of the study design in which significant 
sources of bias may persist. 
Not reported (NR) Should be reserved for those aspects in which the study under review fails to 
report how they have (or might have) been considered. 
Not applicable (NA) Should be reserved for those study design aspects that are not applicable 
given the study design under review (for example, allocation concealment 
would not be applicable for case control studies).  
 
Each study is then awarded an overall study quality grading for internal validity (IV) and a separate 
one for external validity (EV): 
++ All or most of the checklist criteria have been fulfilled, where they have not 
been fulfilled the conclusions are very unlikely to alter. 
+ Some of the checklist criteria have been fulfilled, where they have not been 
fulfilled, or not 
adequately described, the conclusions are unlikely to alter. 
− Few or no checklist criteria have been fulfilled and the conclusions are likely or 
very likely to alter. 
 
Study identification: Griffiths, C., Sturdy, P., Brewin, P., et al., 2007. 
Educational outreach to promote screening for 
tuberculosis in primary care: a cluster randomised 
controlled trial. The Lancet. 369 (9572), 1528-1534. 
Study design: Cluster RCT 
Guidance topic: Tuberculosis: clinical diagnosis and management of 
tuberculosis, and measures for its prevention and 
control (update) 
Assessed by: Theo Lorenc 
Section 1: Population 
1.1 Is the source population or source area 
well described? 
Was the country (e.g. developed or non-
developed, type of healthcare system), 
setting (primary schools, community centres 
etc.), location (urban, rural), population 




Comments: Fairly brief description of source 
1.2 Is the eligible population or area 
representative of the source population or 
area? 
Was the recruitment of individuals, clusters 
or areas well defined (e.g. advertisement, 
birth register)? 





Comments: All attending GP practices in 
Hackney eligible, so can be assumed 
representative, although detailed figures NR 
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of the source? Were important groups 
under-represented? 
1.3 Do the selected participants or areas 
represent the eligible population or area? 
Was the method of selection of participants 
from the eligible population well described? 
What % of selected individuals or clusters 
agreed to participate? Were there any 
sources of bias? 
Were the inclusion or exclusion criteria 





Comments: Clear at practice level, less clear 
at individual patient level 
Section 2: Method of allocation to intervention (or comparison) 
2.1 Allocation to intervention (or 
comparison). How was selection bias 
minimised? 
Was allocation to exposure and comparison 
randomised? Was it truly random ++ or 
pseudo-randomised + (e.g. consecutive 
admissions)? 
If not randomised, was significant 
confounding likely (−) or not (+)? 







Comments: Cluster randomised, full 
description of randomisation procedure 
2.2 Were interventions (and comparisons) 
well described and appropriate? 
Were interventions and comparisons 
described in sufficient detail (i.e. enough for 
study to be replicated)? Was comparisons 







Comments: Full description of intervention 
2.3 Was the allocation concealed? 
Could the person(s) determining allocation 
of participants or clusters to intervention or 
comparison groups have influenced the 
allocation? 
Adequate allocation concealment (++) would 
include centralised allocation or 






Comments: See p28, column 2 
2.4 Were participants or investigators blind 
to exposure and comparison? 
Were participants and investigators – those 
delivering or assessing the intervention kept 
blind to intervention allocation? (Triple or 
double blinding 
score ++) 
If lack of blinding is likely to cause important 








Comments: Participants and deliverers 
couldn't be blinded due to nature of 
intervention. Outcome assessors (record 
coders) were blinded; see end p29. 
2.5 Was the exposure to the intervention 
and comparison adequate? 
Is reduced exposure to intervention or 





Comments: Not described in detail, although 
some checks appear to have been in place 
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adverse effects leading to reduced 
compliance) or fidelity of implementation 
(e.g. reduced adherence to protocol)? 




2.6 Was contamination acceptably low? 
Did any in the comparison group receive the 
intervention or vice versa? 
If so, was it sufficient to cause important 
bias? 
If a cross-over trial, was there a sufficient 









Comments: Not really discussed - could 
assume not because people aren't usually 
registered with >1 GP. 
2.7 Were other interventions similar in 
both groups? 
Did either group receive additional 
interventions or have services provided in a 
different manner? 
Were the groups treated equally by 
researchers or other professionals? 






Comments: Broadly - they do say "Several 
[practices in the control group] were doing 
some tuberculin skin testing before the 
study and continued to do so." 
2.8 Were all participants accounted for at 
study conclusion? 
Were those lost-to-follow-up (i.e. dropped 
or lost pre, during or post-intervention) 
acceptably low (i.e. typically <20%)? 
Did the proportion dropped differ by group? 
For example, were drop-outs related to the 








Comments: At practice level, appear to have 
lost 2 practices because they merged with 
others (table 3 note). At individual patient 
level, NA 
2.9 Did the setting reflect usual UK 
practice? 
Did the setting in which the intervention or 
comparison was delivered differ significantly 
from usual practice in the UK? For example, 
did participants receive intervention (or 
comparison) condition in a hospital rather 







2.10 Did the intervention or control 
comparison reflect usual UK practice? 
Did the intervention or comparison differ 
significantly from usual practice in the UK? 
For example, did participants receive 
intervention (or comparison) delivered by 
specialists rather than GPs? Were 





Comments: The intervention works within 
the existing UK primary care paradigm, and 






Section 3: Outcomes 
3.1 Were outcome measures reliable? 
Were outcome measures subjective or 
objective (e.g. biochemically validated 







Comments: Assume that clinical records are 
reliable, although this is not discussed 
explicitly 
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How reliable were outcome measures (e.g. 
inter- or intra-rater reliability scores)? 
Was there any indication that measures had 
been validated (e.g. validated against a gold 




3.2 Were all outcome measurements 
complete? 
Were all or most study participants who met 
the defined study outcome definitions likely 
to have been identified? 
Score: 
+ 
Comments: Stated that BCG data were not 
available from 7 out of 50 practices (table 3 
note), although unclear why 
 
3.3 Were all important outcomes assessed? 
Were all important benefits and harms 
assessed? 
Was it possible to determine the overall 
balance of benefits and harms of the 





3.4 Were outcomes relevant? 
Where surrogate outcome measures were 
used, did they measure what they set out to 
measure? (e.g. a study to assess impact on 
physical activity assesses gym membership – 
a potentially objective outcome measure – 








3.5 Were there similar follow-up times in 
exposure and comparison groups? 
If groups are followed for different lengths 
of time, then more events are likely to occur 
in the group followed-up for longer 
distorting the comparison. 
Analyses can be adjusted to allow for 








Comments: Not entirely clear 
3.6 Was follow-up time meaningful? 
Was follow-up long enough to assess long-
term benefits or harms? 





Comments: Unclear: data were collected 
from June 2002 - Sept 2004, but timing of 
intervention implementation with regards to 
this doesn't seem to be reported. But follow-
up time is reasonable on the assumption 
that something was already happening at 
the beginning of that period. 
Section 4: Analyses 
4.1 Were exposure and comparison groups 
similar at baseline? If not, were these 
adjusted? 
Were there any differences between groups 
in important confounders at baseline? 
If so, were these adjusted for in the analyses 
(e.g. multivariate analyses or stratification). 
Were there likely to be any residual 








Comments: Full detail given 
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4.2 Was intention to treat (ITT) analysis 
conducted? 
Were all participants (including those that 
dropped out or did not fully complete the 
intervention course) analysed in the groups 
(i.e. intervention or comparison) to which 







4.3 Was the study sufficiently powered to 
detect an intervention effect (if one exists)? 
A power of 0.8 (that is, it is likely to see an 
effect of a given size if one exists, 80% of the 
time) is the conventionally accepted 
standard. 
Is a power calculation presented? If not, 
what is the expected effect size? 








Comments: Power calculation reported 
4.4 Were the estimates of effect size given 
or calculable? 
Were effect estimates (e.g. relative risks, 




Comments: Effect sizes reported 
4.5 Were the analytical methods 
appropriate? 
Were important differences in follow-up 
time and likely confounders adjusted for? 
If a cluster design, were analyses of sample 
size (and power), and effect size performed 
on clusters (and not individuals)? 









4.6 Was the precision of intervention 
effects given or calculable? Were they 
meaningful? 
Were confidence intervals or p values for 
effect estimates given or possible to 
calculate? 
Were CI's wide or were they sufficiently 
precise to aid decision-making? If precision 










Section 5: Summary 
5.1 Are the study results internally valid 
(i.e. unbiased)? 
How well did the study minimise sources of 
bias (i.e. adjusting for potential 
confounders)? 










5.2 Are the findings generalisable to the 
source population (i.e. externally valid)? 
Are there sufficient details given about the 
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generalisable to the source population? 
Consider: participants, interventions and 
comparisons, outcomes, resource and policy 
implications. 
 
 
 
 
 
 
 
